Evidence map›Paper›PMID 39342503›Full record

ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2024

Neoadjuvant Capecitabine in Operable HPV-Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting.

Marco A Mascarella, Keith Richardson, Alex Mlynarek, Michael P Hier, Derin Caglar, Livia Florianova, Marc Philippe Pusztaszeri, Khalil Sultanem, Nader Sadeghi, Nathaniel Bouganim and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marco A MascarellaDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.ORCID 0000-0002-8880-805X
Keith RichardsonDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
Alex MlynarekDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
Michael P HierDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
Derin CaglarDepartment of Anatomical Pathology, McGill University, Montreal, Canada.
Livia FlorianovaDepartment of Anatomical Pathology, McGill University, Montreal, Canada.
Marc Philippe PusztaszeriDepartment of Anatomical Pathology, McGill University, Montreal, Canada.
Khalil SultanemDivision of Radiation Oncology, Department of Oncology, Jewish General Hospital, Montreal, Canada.
Nader SadeghiDepartment of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
Nathaniel BouganimDivision of Medical Oncology, Department of Medicine, McGill University, Montreal, Canada.
Khashayar EsfahaniMcGill Centre for Translational Research in Cancer, McGill University, Montreal, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLimited progress has occurred in treating operable human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). Accessing timely care remains challenging in public health care systems, potentially resulting in disease progression before treatment initiation. STUDY

designA prospective cohort of patients receiving neoadjuvant capecitabine (NC) was compared to stage-matched patients undergoing standard of care (SC).

settingThis study was performed at 2 academic centers in Montreal, Canada.

methodsTo ascertain the effect of 2 cycles of NC in operable HPV-negative HNSCC patients on clinical-to-pathologic stage migration. Comparison to an SC group was performed to site and TNM stage matched patients. Pathologic treatment response was measured using the modified Ryan score.

resultsWe compared 16 NC patients (11 oral cavity, 3 skin, 2 larynx) with 32 SC patients. Ten NC patients exhibited a pathologic response (1 complete, 3 major, 6 minor). Clinical-to-pathologic stage migration differed significantly between NC and SC groups: downstage (6 vs 1), upstage (3 vs 14), no change (7 vs 17, P = .0047). There was no severe treatment toxicity related to capecitabine. All patients in the NC group underwent surgery.

conclusionNC followed by surgery demonstrates measurable pathologic response in HPV-negative HNSCC, suggesting potential utility in resource-limited health care settings.

Indexed as

CapecitabineHead and Neck NeoplasmsNeoadjuvant TherapyAdultAgedAntimetabolites, AntineoplasticCarcinoma, Squamous CellDeoxycytidineFemaleFluorouracilHumansMaleMiddle AgedNeoplasm StagingProspective StudiesSquamous Cell Carcinoma of Head and NeckAntimetabolites, AntineoplasticCapecitabineDeoxycytidineFluorouracilhealth care systemHPV‐negative cancerneoadjuvant capecitabinepathologic responsestage migrationsurgery

Identifiers

PMID39342503
PMCPMC11605015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.